Our Science
Pressing the Reset Button on the Immune System
Our Revolutionary Approach
People with autoimmune or allergic diseases often have overactive, dysfunctional immune systems characterized by elevated numbers of inflammatory immune cells, leading to tissue destruction.
In allergic diseases, the immune system “overreacts” to certain molecules (allergic antigens) that are unknown to the body. In autoimmune diseases, the body recognizes its own tissues (self-antigens) as if they were foreign and attacks them. As part of that recognition a type of immune cell known as a monocyte, interacts with and engulfs these antigens and then matures into specialized immune cells called dendritic cells.
Dendritic cells interact with naïve T cells, another undifferentiated cell type, and deliver an activating signal for naive T cells to become inflammatory T effector cells that multiply and drive chronic inflammation and tissue destruction.
Revolo’s molecules, ‘1805 and ‘1104, reset the immune system “upstream,” or ahead of the inflammatory cascade.
Our drug candidates, ‘1805 and ‘1104, bind to monocytes as they mature into dendritic cells, prompting delivery of a modified “regulatory” signal to naïve T cells, generating activated T regulatory cells (Tregs) instead of T effector cells.
Tregs prevent the immune system from entering overdrive. ‘1805 and ‘1104 uniquely reset the immune system to its normal regulatory state and may lead to long-term disease remission.
